MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
BioVie Cash Conversion Cycle 2011-2025 | BIVI
Quarterly Cash Conversion Cycle BioVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -689 | - | -1.13 K | -702 | -600 | -301 | -625 | -568 | -432 | -432 | -244 | -11.5 | -11.5 | -1.47 | -6.32 | -7.62 | -2.01 | -2.83 | -2.79 | -14 | -25.6 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.47 | -1.13 K | -290 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
285 | $ 223.01 | -0.99 % | $ 395 B |  USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.68 | 1.85 % | $ 777 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-881 | $ 3.38 | 3.21 % | $ 261 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Aptorum Group Limited
APM
|
-400 | $ 1.33 | -1.48 % | $ 7.25 M |  China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
-58 | $ 90.34 | -1.28 % | $ 96.9 B | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 25.76 | 0.19 % | $ 1.25 B | USA |
 |
Anika Therapeutics
ANIK
|
270 | $ 9.53 | -1.19 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
387 | $ 173.03 | -2.55 % | $ 25.2 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
214 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.33 | 2.3 % | $ 14.6 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Baudax Bio
BXRX
|
-14.3 | - | 0.59 % | $ 63 K | USA |
 |
Catalyst Biosciences
CBIO
|
391 | $ 15.32 | 5.73 % | $ 1.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
23.8 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
86.2 | $ 586.28 | 3.15 % | $ 44.4 B | USA |
 |
Cerus Corporation
CERS
|
59.2 | $ 2.14 | 13.23 % | $ 395 M | USA |
 |
Caladrius Biosciences
CLBS
|
164 | - | -16.75 % | $ 25.8 M | USA |
 |
Celldex Therapeutics
CLDX
|
-6.08 K | $ 28.33 | 0.5 % | $ 1.82 M | USA |
 |
Clovis Oncology
CLVS
|
65.5 | - | -7.23 % | $ 13 M | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 12.91 | 0.78 % | $ 531 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
177 | $ 60.38 | 0.11 % | $ 6.76 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
209 | $ 11.55 | 8.86 % | $ 747 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
459 | $ 10.89 | -0.09 % | $ 1.42 B | USA |